AVBP - ArriVent BioPharma, Inc. Common Stock
NEXT EARNINGS:
Mar 2, 2026
(in 5 days)
EPS Est: $-0.87
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$44.00
DETAILS
HIGH:
$45.00
LOW:
$43.00
MEDIAN:
$44.00
CONSENSUS:
$44.00
UPSIDE:
88.84%
Market Cap:
961.86M
Volume:
230,913
Avg Volume:
457,200
52 Week Range:
15.47-27.85
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.03
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
52
IPO Date:
2024-01-26
EPS (TTM):
-2.56
P/E Ratio:
-10.42
Revenue (TTM):
N/A
Total Assets:
274.94M
Total Debt:
176,000
Cash & Equiv:
74.29M
Rev Growth (5Y):
N/A
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-31.2%
Debt/Equity:
0.00
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-10 | $-0.83 | $-0.78 | -6.4% | — | — | — |
| 2025-08-11 | $-0.90 | $-0.70 | -28.6% | — | — | — |
| 2025-05-12 | $-1.90 | $-0.66 | -187.9% | — | — | — |
| 2025-03-03 | $-0.60 | $-0.78 | +23.1% | — | — | — |
| 2024-11-14 | $-0.61 | $-0.82 | +25.6% | — | — | — |
| 2024-08-14 | $-0.65 | $-0.65 | 0.0% | — | — | — |
| 2024-05-08 | $-0.70 | $-0.84 | +16.7% | — | — | — |
| 2024-01-26 | $-0.70 | $-1.10 | +36.4% | — | — | — |
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Net Income | (80.49M) | (69.33M) | (36.91M) | (51.61M) |
| EPS | -2.56 | -2.17 | -1.10 | -40.44 |
| Total Assets | 274.94M | 163.10M | 182.83M | 43.04M |
| Total Debt | 176,000 | 317,000 | 139,000 | 0 |
| Cash & Equivalents | 74.29M | 150.39M | 163.37M | 37.28M |
| Operating Cash Flow | (70.21M) | (55.84M) | (43.63M) | (12.59M) |
| Free Cash Flow | (70.21M) | (55.84M) | (43.63M) | (12.59M) |
| FCF per Share | -2.23 | -1.75 | -1.30 | -9.86 |
| Book Value | 257.65M | 151.30M | 174.46M | 41.22M |
| Cash & ST Investments | 218.86M | 150.39M | 163.37M | 37.28M |
| ROC Equity | -0.31 | -0.46 | -0.21 | -1.25 |